Sanders RW, Moore JP.
2024.
Progress on priming HIV-1 immunity.. Science. 384(6697):738-739.
Ross CF, Brougham MJ, Holloman WK, Ross WE.
1983.
Properties of a purified nuclear topoisomerase from L1210 cells.. Biochim Biophys Acta. 741(2):230-6.
Giardina SF, Valdambrini E, J Warren D, Barany F.
2021.
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.. Curr Cancer Drug Targets. 21(4):306-325.
K Darwin H, Ehrt S, Gutierrez-Ramos J-C, Weich N, Nathan CF.
2003.
The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.. Science. 302(5652):1963-6.
Nathan C, Calingasan N, Nezezon J, Ding A, M Lucia S, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NSoo et al..
2005.
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase.. J Exp Med. 202(9):1163-9.
Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al..
2005.
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.
Rowe TC, Rusche JR, Brougham MJ, Holloman WK.
1981.
Purification and properties of a topoisomerase from Ustilago maydis.. J Biol Chem. 256(20):10354-61.
Yarnall M, Rowe TC, Holloman WK.
1984.
Purification and properties of nuclease gamma from Ustilago maydis.. J Biol Chem. 259(5):3026-32.